To include your compound in the COVID-19 Resource Center, submit it here.

IL-17A's autoimmune dichotomy

Why blocking IL-17A has differing effects in Crohn's and psoriasis

A pair of studies has resolved the conundrum of why blocking IL-17A helps in psoriasis but exacerbates Crohn's disease, and highlights the dangers of assuming that hitting a target in autoimmunity will have the same outcome, regardless of indication. The findings suggest the different pathologies of seemingly similar autoimmune diseases make targeting general mechanisms riskier than companies may have bargained for.

In two papers published in Immunity, groups from Amgen

Read the full 690 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers